- List
- By Topic
- On Map
- Search Details

Hemostatic | Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma"
Need help? See RSS Feeds
Choose a feed type:

Hemostatic | Recruiting, Not yet recruiting, Available Studies | "Multiple Myeloma" (492 records)
Need help? See Downloading Content for Analysis
For Advanced Users: Full Study Record XML Download
1 | NCT03506386 | Recruiting | Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis |
|
Observational |
|
Industry |
|
|
1000 | All | 18 Years and older (Adult, Older Adult) | NCT03506386 | NDMM-5004 | MMyBRave | August 9, 2018 | August 1, 2019 | August 1, 2019 | April 24, 2018 | December 17, 2018 |
|
||||
2 | NCT03670173 | Not yet recruiting | Safety and Efficacy Assessments of Osalmid in Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT03670173 | STPH-MM001 | October 1, 2018 | January 31, 2020 | September 30, 2020 | September 13, 2018 | September 13, 2018 | ||||
3 | NCT03757221 | Not yet recruiting | Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
70 | All | 65 Years and older (Older Adult) | NCT03757221 | 18-070 | IDARA | January 1, 2019 | December 31, 2024 | December 31, 2025 | November 28, 2018 | November 28, 2018 | |||
4 | NCT03782064 | Not yet recruiting | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
25 | All | 18 Years and older (Adult, Older Adult) | NCT03782064 | 18-280 | January 31, 2019 | January 31, 2022 | January 31, 2025 | December 20, 2018 | December 20, 2018 |
|
|||
5 | NCT03657420 | Not yet recruiting | Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
28 | All | 18 Years and older (Adult, Older Adult) | NCT03657420 | 18-252 | September 30, 2018 | September 30, 2021 | September 30, 2024 | September 5, 2018 | September 5, 2018 |
|
|||
6 | NCT03091257 | Recruiting | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT03091257 | 16-352 | June 21, 2017 | December 2020 | December 2021 | March 27, 2017 | October 5, 2018 |
|
|||
7 | NCT03127761 | Recruiting | Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma |
|
|
Observational |
|
Other |
|
|
544 | All | Child, Adult, Older Adult | NCT03127761 | 17-CMS-MM | July 25, 2017 | May 2027 | April 2028 | April 25, 2017 | September 13, 2017 |
|
||||
8 | NCT03839459 | Not yet recruiting New |
Denosumab for Smoldering Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
20 | All | 18 Years and older (Adult, Older Adult) | NCT03839459 | UMMY18121 | March 1, 2019 | March 1, 2021 | March 1, 2024 | February 15, 2019 | February 15, 2019 | ||||
9 | NCT03379584 | Recruiting | A Safety Study of SGN-CD48A in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
85 | All | 18 Years and older (Adult, Older Adult) | NCT03379584 | SGN48A-001 | February 20, 2018 | August 2020 | December 2021 | December 20, 2017 | February 4, 2019 |
|
|||
10 | NCT03104270 | Recruiting | Combination Study for High Risk Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03104270 | CA204-187 | March 13, 2017 | February 2020 | May 2020 | April 7, 2017 | January 8, 2019 |
|
|||
11 | NCT03492138 | Recruiting | Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
42 | All | 18 Years and older (Adult, Older Adult) | NCT03492138 | GCO 17-2680 | March 26, 2018 | March 15, 2023 | March 15, 2023 | April 10, 2018 | April 10, 2018 |
|
|||
12 | NCT02963493 | Recruiting | A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry / Other |
|
|
150 | All | 18 Years and older (Adult, Older Adult) | NCT02963493 | OP-106 | HORIZON | December 2016 | March 2020 | November 2021 | November 15, 2016 | November 27, 2018 |
|
||
13 | NCT02718833 | Recruiting | A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
46 | All | 18 Years and older (Adult, Older Adult) | NCT02718833 | 15-475 | June 2016 | September 2019 | September 2023 | March 24, 2016 | August 7, 2018 |
|
|||
14 | NCT02916771 | Recruiting | Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT02916771 | 16-313 | October 2016 | April 2020 | April 2024 | September 27, 2016 | January 7, 2019 |
|
|||
15 | NCT02416206 | Recruiting | High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
65 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT02416206 | NSH 1107 | April 27, 2015 | December 2019 | May 2020 | April 14, 2015 | December 10, 2018 |
|
|||
16 | NCT03549442 | Recruiting | Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT03549442 | 828773 | May 9, 2018 | May 2020 | May 2021 | June 8, 2018 | June 20, 2018 |
|
|||
17 | NCT02833610 | Recruiting | A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
55 | All | 18 Years and older (Adult, Older Adult) | NCT02833610 | 15-571 | August 2016 | October 2019 | October 2023 | July 14, 2016 | October 5, 2018 |
|
|||
18 | NCT03767725 | Recruiting | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
10 | All | 14 Years to 75 Years (Child, Adult, Older Adult) | NCT03767725 | Weihong Chen06082018 | June 2, 2018 | June 1, 2021 | September 1, 2021 | December 7, 2018 | December 10, 2018 |
|
|||
19 | NCT03651128 | Not yet recruiting | Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
381 | All | 18 Years and older (Adult, Older Adult) | NCT03651128 | BB2121-MM-003 U1111-1217-9988 2018-001023-38 |
KarMMa-3 | November 30, 2018 | June 9, 2025 | June 9, 2025 | August 29, 2018 | October 25, 2018 |
|
||
20 | NCT03287804 | Recruiting | APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
80 | All | 18 Years and older (Adult, Older Adult) | NCT03287804 | AUTO2-MM1 2016-003893-42 |
APRIL | May 5, 2017 | October 2020 | October 2020 | September 19, 2017 | July 10, 2018 |
|
||
21 | NCT03601078 | Recruiting | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
181 | All | 18 Years and older (Adult, Older Adult) | NCT03601078 | BB2121-MM-002 U1111-1216-4209 2018-000264-28 |
KarMMa-2 | December 13, 2018 | March 12, 2025 | March 12, 2025 | July 26, 2018 | February 8, 2019 |
|
||
22 | NCT02902900 | Recruiting | An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice |
|
Observational |
|
Industry |
|
|
3000 | All | 18 Years and older (Adult, Older Adult) | NCT02902900 | CC-4047-MM-018 | MIROIR | September 25, 2015 | September 30, 2019 | September 30, 2020 | September 16, 2016 | November 15, 2018 |
|
||||
23 | NCT03292263 | Recruiting | ASCT With Nivolumab in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
30 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03292263 | 11/17-n | April 24, 2017 | April 2019 | April 2021 | September 25, 2017 | September 25, 2017 |
|
|||
24 | NCT02967276 | Recruiting | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
28 | All | 18 Years and older (Adult, Older Adult) | NCT02967276 | METDEXA-MM | METDEXA-MM | January 2017 | February 2018 | February 2020 | November 18, 2016 | May 2, 2017 |
|
||
25 | NCT03539744 | Recruiting | A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
244 | All | 18 Years and older (Adult, Older Adult) | NCT03539744 | M13-494 | CANOVA | October 22, 2018 | January 12, 2021 | January 27, 2022 | May 28, 2018 | February 12, 2019 |
|
||
26 | NCT03033316 | Not yet recruiting | A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry / Other |
|
|
35 | All | 18 Years and older (Adult, Older Adult) | NCT03033316 | 14-097 | AMETHYST | January 2017 | December 2018 | March 2019 | January 26, 2017 | January 26, 2017 | |||
27 | NCT02899052 | Recruiting | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT02899052 | M15-538 | January 19, 2017 | March 27, 2020 | October 16, 2022 | September 14, 2016 | October 31, 2018 |
|
|||
28 | NCT03393273 | Not yet recruiting | Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
35 | All | 66 Years and older (Older Adult) | NCT03393273 | P170103 2017-001446-10 |
IFM2016-03 | May 2018 | May 2023 | May 2023 | January 8, 2018 | May 15, 2018 | |||
29 | NCT02248428 | Recruiting | Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
130 | All | 18 Years and older (Adult, Older Adult) | NCT02248428 | NAB20140324 | CTd | April 2012 | September 2019 | September 2020 | September 25, 2014 | September 6, 2017 |
|
||
30 | NCT01453088 | Recruiting | Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
208 | All | 60 Years and older (Adult, Older Adult) | NCT01453088 | PRO# 1307 | June 24, 2010 | March 2020 | March 2020 | October 17, 2011 | August 7, 2018 |
|
|||
31 | NCT02188368 | Recruiting | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
45 | All | 18 Years and older (Adult, Older Adult) | NCT02188368 | PO-CL-MM-PI-003854 | August 2014 | December 2018 | December 2018 | July 11, 2014 | October 5, 2018 |
|
|||
32 | NCT03785184 | Not yet recruiting | A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
40 | All | 18 Years and older (Adult, Older Adult) | NCT03785184 | M16-104 | March 29, 2019 | April 3, 2024 | September 26, 2027 | December 24, 2018 | December 24, 2018 |
|
|||
33 | NCT02939183 | Recruiting | Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
64 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT02939183 | 20160104 | INTREPID-1 | January 17, 2017 | April 29, 2020 | April 29, 2020 | October 19, 2016 | February 8, 2019 |
|
||
34 | NCT02519452 | Recruiting | A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
108 | All | 18 Years and older (Adult, Older Adult) | NCT02519452 | CR107838 2015-001210-94 54767414MMY1004 |
October 22, 2015 | December 13, 2017 | June 17, 2021 | August 11, 2015 | February 4, 2019 |
|
|||
35 | NCT03815279 | Not yet recruiting New |
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
80 | All | 18 Years and older (Adult, Older Adult) | NCT03815279 | LSH-17-001 | iStopMM | February 2019 | January 2024 | January 2028 | January 24, 2019 | January 24, 2019 |
|
||
36 | NCT01794520 | Recruiting | Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
166 | All | 18 Years and older (Adult, Older Adult) | NCT01794520 | M13-367 2012-000589-38 |
October 10, 2012 | May 29, 2021 | May 29, 2021 | February 20, 2013 | February 15, 2019 |
|
|||
37 | NCT03110562 | Recruiting | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Industry |
|
|
364 | All | 18 Years and older (Adult, Older Adult) | NCT03110562 | KCP-330-023 | BOSTON | May 24, 2017 | June 2020 | June 2020 | April 12, 2017 | November 2, 2018 |
|
||
38 | NCT03795597 | Not yet recruiting | Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT03795597 | 209274 | BuMelCarAuto | February 1, 2019 | November 1, 2021 | November 1, 2023 | January 8, 2019 | January 8, 2019 | |||
39 | NCT03110822 | Recruiting | A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
49 | All | 18 Years and older (Adult, Older Adult) | NCT03110822 | I-RUX-15-04 | February 1, 2017 | February 2020 | May 2020 | April 12, 2017 | November 29, 2018 |
|
|||
40 | NCT03001804 | Recruiting | Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients |
|
Observational |
|
Industry |
|
|
56 | All | 18 Years and older (Adult, Older Adult) | NCT03001804 | CC-5013-MM-037 | July 31, 2017 | December 30, 2021 | December 31, 2021 | December 23, 2016 | January 30, 2019 |
|
|||||
41 | NCT03486067 | Recruiting | Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
120 | All | 18 Years and older (Adult, Older Adult) | NCT03486067 | CC-93269-MM-001 U1111-1210-6325 2017-003448-19 |
April 3, 2018 | July 26, 2021 | June 16, 2022 | April 3, 2018 | December 3, 2018 |
|
|||
42 | NCT03271632 | Recruiting | Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
20 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03271632 | GIMI-IRB-17013 | July 15, 2017 | December 31, 2019 | December 31, 2020 | September 5, 2017 | February 26, 2018 |
|
|||
43 | NCT03421132 | Recruiting | Multiple Myeloma Molecular Monitoring Study |
|
Observational |
|
Other |
|
|
250 | All | 19 Years to 99 Years (Adult, Older Adult) | NCT03421132 | M4 | M4 | February 20, 2018 | December 2021 | June 2022 | February 2, 2018 | October 16, 2018 |
|
||||
44 | NCT03762291 | Not yet recruiting | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
24 | All | 18 Years and older (Adult, Older Adult) | NCT03762291 | H-42712 MAPSS | MAPSS | January 1, 2019 | January 1, 2022 | November 1, 2026 | December 3, 2018 | December 3, 2018 | |||
45 | NCT03582033 | Recruiting | A Safety Study of SEA-BCMA in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
65 | All | 18 Years and older (Adult, Older Adult) | NCT03582033 | SGNBCMA-001 | November 1, 2018 | September 2021 | June 2022 | July 10, 2018 | February 4, 2019 |
|
|||
46 | NCT02278315 | Recruiting | Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
33 | All | 18 Years and older (Adult, Older Adult) | NCT02278315 | DCL-14-002 | February 2015 | June 2019 | September 2019 | October 30, 2014 | January 8, 2019 |
|
|||
47 | NCT03779815 | Recruiting | Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
18 | All | 19 Years and older (Adult, Older Adult) | NCT03779815 | UUH-2018-05-034-001 | PET | August 20, 2018 | February 2019 | February 2019 | December 19, 2018 | December 25, 2018 |
|
||
48 | NCT02294357 | Recruiting | Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
45 | All | 18 Years and older (Adult, Older Adult) | NCT02294357 | IST-CAR-2014-100701 (20159897) | December 2014 | November 2018 | December 2018 | November 19, 2014 | October 5, 2018 |
|
|||
49 | NCT02555839 | Recruiting | Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice |
|
|
Observational |
|
Industry |
|
|
70 | All | 18 Years and older (Adult, Older Adult) | NCT02555839 | CC-4047-MM-017 | March 1, 2015 | September 30, 2019 | September 30, 2019 | September 22, 2015 | November 14, 2018 |
|
||||
50 | NCT03828292 | Not yet recruiting New |
An Open-label, Dose Escalation Study in Japanese Subjects With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
12 | All | 20 Years and older (Adult, Older Adult) | NCT03828292 | 207504 | February 7, 2019 | October 2, 2019 | March 31, 2020 | February 4, 2019 | February 4, 2019 |
|
|||
51 | NCT02946333 | Recruiting | A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain |
|
Observational |
|
Industry |
|
|
450 | All | 18 Years and older (Adult, Older Adult) | NCT02946333 | CEL-MIE-2016-01 | QoLMMBuS | November 25, 2016 | October 10, 2020 | October 30, 2025 | October 27, 2016 | July 12, 2018 |
|
||||
52 | NCT03111992 | Recruiting | Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
70 | All | 18 Years and older (Adult, Older Adult) | NCT03111992 | CPDR001X2106 | December 18, 2017 | May 27, 2020 | May 27, 2020 | April 13, 2017 | January 21, 2019 |
|
|||
53 | NCT03544281 | Recruiting | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
90 | All | 18 Years and older (Adult, Older Adult) | NCT03544281 | 207497 | September 20, 2018 | June 29, 2020 | November 28, 2022 | June 1, 2018 | October 12, 2018 |
|
|||
54 | NCT03376477 | Recruiting | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
56 | All | 18 Years and older (Adult, Older Adult) | NCT03376477 | J16118 IRB00112179 |
July 10, 2018 | October 16, 2020 | October 16, 2023 | December 18, 2017 | September 6, 2018 |
|
|||
55 | NCT03288974 | Recruiting | Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea |
|
|
Observational |
|
Industry |
|
|
600 | All | 19 Years and older (Adult, Older Adult) | NCT03288974 | NIPMS-POM-KR-001 U1111-1201-1712 |
Pomalyst PMS | December 28, 2017 | June 8, 2023 | June 8, 2023 | September 20, 2017 | May 21, 2018 |
|
|||
56 | NCT03669445 | Recruiting | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
45 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03669445 | RC31/18/0212 | IFM2018-01 | December 31, 2018 | March 2024 | December 2024 | September 13, 2018 | February 4, 2019 |
|
||
57 | NCT03525678 | Recruiting | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
155 | All | 18 Years and older (Adult, Older Adult) | NCT03525678 | 205678 | June 18, 2018 | June 30, 2019 | June 30, 2020 | May 16, 2018 | October 12, 2018 |
|
|||
58 | NCT02291848 | Recruiting | Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other |
|
|
36 | All | 18 Years and older (Adult, Older Adult) | NCT02291848 | H-35626, TACTAM | TACTAM | April 2015 | April 2019 | April 2021 | November 17, 2014 | November 9, 2018 |
|
||
59 | NCT03490084 | Not yet recruiting | Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma |
|
|
Observational |
|
Other |
|
|
300 | All | 65 Years and older (Older Adult) | NCT03490084 | P_PREPS 16-596 | PAMM-HAD1 | January 2019 | September 2021 | September 2021 | April 6, 2018 | October 16, 2018 |
|
|||
60 | NCT03224507 | Recruiting | Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
82 | All | 18 Years and older (Adult, Older Adult) | NCT03224507 | F170525008 (UAB 1735) | MASTER | March 14, 2018 | April 1, 2021 | April 1, 2023 | July 21, 2017 | January 14, 2019 |
|
||
61 | NCT02969837 | Recruiting | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
55 | All | 18 Years and older (Adult, Older Adult) | NCT02969837 | IRB16-1138 | July 10, 2017 | December 2019 | December 2020 | November 21, 2016 | February 21, 2018 |
|
|||
62 | NCT03314181 | Recruiting | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
90 | All | 18 Years and older (Adult, Older Adult) | NCT03314181 | M15-654 2017-002099-26 |
March 12, 2018 | November 4, 2020 | March 22, 2023 | October 19, 2017 | February 11, 2019 |
|
|||
63 | NCT03804424 | Recruiting | 64Cu-LLP2A for Imaging Multiple Myeloma |
|
|
Interventional |
Early Phase 1 |
|
Other |
|
|
32 | All | 18 Years and older (Adult, Older Adult) | NCT03804424 | 201807197 | November 20, 2018 | November 30, 2020 | November 30, 2020 | January 15, 2019 | January 15, 2019 |
|
|||
64 | NCT03567616 | Recruiting | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
60 | All | 18 Years and older (Adult, Older Adult) | NCT03567616 | M16-085 | November 9, 2018 | August 20, 2020 | January 22, 2021 | June 25, 2018 | February 8, 2019 |
|
|||
65 | NCT03269136 | Recruiting | Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
80 | All | 18 Years and older (Adult, Older Adult) | NCT03269136 | C1071001 | November 29, 2017 | June 5, 2021 | February 13, 2022 | August 31, 2017 | November 19, 2018 |
|
|||
66 | NCT03689595 | Not yet recruiting | Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) |
|
|
Observational |
|
Other |
|
|
50000 | All | 45 Years to 75 Years (Adult, Older Adult) | NCT03689595 | 18-370 | October 31, 2018 | October 31, 2033 | October 31, 2033 | September 28, 2018 | September 28, 2018 |
|
||||
67 | NCT02692339 | Recruiting | Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Observational |
|
Industry |
|
|
120 | All | 18 Years and older (Adult, Older Adult) | NCT02692339 | CC-5013-MM-028 | PrObe-L | February 25, 2016 | September 29, 2023 | September 29, 2023 | February 26, 2016 | March 6, 2018 |
|
|||
68 | NCT03374085 | Recruiting | A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
80 | All | 18 Years and older (Adult, Older Adult) | NCT03374085 | CC-92480-MM-001 U1111-1205-3650 2017-001236-19 |
February 6, 2018 | January 1, 2020 | March 1, 2020 | December 15, 2017 | August 24, 2018 |
|
|||
69 | NCT03430011 | Recruiting | Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
118 | All | 18 Years and older (Adult, Older Adult) | NCT03430011 | H125001 | EVOLVE | February 1, 2018 | March 2021 | March 2021 | February 12, 2018 | February 11, 2019 |
|
||
70 | NCT03733691 | Not yet recruiting | Phase 2 Maintenance Trial: Ixazomib Compared to Ixazomib-Lenalidomide Combination as Maintenance Therapy for Frontline Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
52 | All | 18 Years to 100 Years (Adult, Older Adult) | NCT03733691 | X16108 | December 20, 2018 | December 20, 2023 | February 20, 2024 | November 7, 2018 | November 9, 2018 | ||||
71 | NCT02869555 | Recruiting | Institut Paoli Calmettes Multiple Myeloma Database |
|
|
Observational |
|
Other |
|
|
5000 | All | 18 Years to 95 Years (Adult, Older Adult) | NCT02869555 | BDD-MYELOME-IPC | January 2010 | January 2030 | December 2030 | August 17, 2016 | August 17, 2016 |
|
||||
72 | NCT02659293 | Recruiting | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma |
|
|
Interventional |
Phase 3 |
|
Other |
|
|
180 | All | 18 Years and older (Adult, Older Adult) | NCT02659293 | IRB15-1286 | April 26, 2016 | March 2019 | May 2020 | January 20, 2016 | March 13, 2018 |
|
|||
73 | NCT02627261 | Recruiting | Multiple Myeloma Minimal Residual Disease |
|
|
Observational |
|
Other / Industry |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT02627261 | 69HCL15_0316 | MMRD | November 2015 | May 2022 | May 2022 | December 10, 2015 | August 1, 2017 |
|
|||
74 | NCT03695744 | Not yet recruiting | Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
63 | All | 18 Years to 85 Years (Adult, Older Adult) | NCT03695744 | AMN006 | October 2018 | March 2021 | October 2023 | October 4, 2018 | October 4, 2018 |
|
|||
75 | NCT02911571 | Recruiting | PRospective Multiple Myeloma Impact Study |
|
|
Interventional |
Not Applicable |
|
Industry / Other |
|
|
250 | All | 18 Years and older (Adult, Older Adult) | NCT02911571 | PROMMIS | PROMMIS | February 27, 2018 | June 15, 2020 | December 1, 2024 | September 22, 2016 | December 3, 2018 |
|
||
76 | NCT03106324 | Recruiting | A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant |
|
|
Observational |
|
Industry |
|
|
888 | All | 18 Years and older (Adult, Older Adult) | NCT03106324 | CC-5013-MM-034 U1111-1194-5810 |
March 31, 2017 | March 31, 2025 | March 31, 2025 | April 10, 2017 | December 11, 2018 |
|
||||
77 | NCT03606577 | Not yet recruiting | An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
50 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03606577 | RC18_0206 | IFM 2018-04 | November 2, 2018 | February 2, 2020 | November 2, 2026 | July 31, 2018 | October 5, 2018 |
|
||
78 | NCT03520985 | Recruiting | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other |
|
|
110 | All | 18 Years and older (Adult, Older Adult) | NCT03520985 | SAKK 39/16 - OptiPOM | OptiPOM | October 1, 2018 | March 2023 | December 2025 | May 10, 2018 | January 23, 2019 |
|
||
79 | NCT03417284 | Not yet recruiting | Evomela Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (AutoSCT) for Multiple Myeloma (MM) |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
60 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03417284 | 2017-0399 NCI-2018-00906 |
February 2019 | August 2020 | August 2020 | January 31, 2018 | December 25, 2018 |
|
|||
80 | NCT03777410 | Not yet recruiting | Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma |
|
Observational |
|
Industry / Other |
|
|
110 | All | 18 Years and older (Adult, Older Adult) | NCT03777410 | TRV-001 | January 2019 | January 2020 | January 2021 | December 17, 2018 | December 17, 2018 | ||||||
81 | NCT03759093 | Not yet recruiting | CURATE.AI Optimized Modulation for Multiple Myeloma |
|
|
Interventional |
Phase 2 Phase 3 |
|
Other |
|
|
20 | All | 21 Years to 99 Years (Adult, Older Adult) | NCT03759093 | 2015/00280 | January 1, 2019 | January 1, 2021 | January 1, 2021 | November 29, 2018 | November 29, 2018 |
|
|||
82 | NCT03763370 | Available | Compassionate Use Individual Request Program for GSK2857916 in Multiple Myeloma |
|
|
Expanded Access
|
|
Industry | All | 18 Years and older (Adult, Older Adult) | NCT03763370 | 209233 | December 4, 2018 | December 4, 2018 | |||||||||||
83 | NCT03322735 | Recruiting | Study of BCMA CAR-T in Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
10 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT03322735 | HenanCH284 | December 8, 2017 | October 2018 | December 2019 | October 26, 2017 | December 29, 2017 |
|
|||
84 | NCT02955550 | Recruiting | A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM) |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
46 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT02955550 | CCT-PNK-007-MM-001 | January 19, 2017 | April 30, 2020 | April 30, 2020 | November 4, 2016 | March 1, 2018 |
|
|||
85 | NCT03274219 | Recruiting | Study of bb21217 in Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
50 | All | 18 Years and older (Adult, Older Adult) | NCT03274219 | CRB-402 | August 16, 2017 | June 2020 | June 2020 | September 6, 2017 | February 4, 2019 |
|
|||
86 | NCT03660072 | Not yet recruiting | Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma |
|
|
Observational |
|
Industry |
|
|
96 | All | 19 Years and older (Adult, Older Adult) | NCT03660072 | CA204-176 | January 31, 2019 | February 10, 2023 | December 29, 2023 | September 6, 2018 | January 15, 2019 |
|
||||
87 | NCT02343042 | Recruiting | Selinexor and Backbone Treatments of Multiple Myeloma Patients |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
321 | All | 18 Years and older (Adult, Older Adult) | NCT02343042 | KCP-330-017 | STOMP | October 2015 | March 2019 | April 2019 | January 21, 2015 | October 16, 2018 |
|
||
88 | NCT03406091 | Recruiting | Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients |
|
|
Observational |
|
Other |
|
|
300 | All | 18 Years and older (Adult, Older Adult) | NCT03406091 | MOZOBL06877 | November 26, 2015 | February 28, 2019 | January 31, 2022 | January 23, 2018 | January 23, 2018 |
|
||||
89 | NCT03777306 | Recruiting | The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma |
|
|
Interventional |
Not Applicable |
|
Other |
|
|
100 | All | 18 Years and older (Adult, Older Adult) | NCT03777306 | IRB-300000121 | November 27, 2017 | September 17, 2019 | September 17, 2020 | December 17, 2018 | December 17, 2018 |
|
|||
90 | NCT03126617 | Available | Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma |
|
|
Expanded Access
|
|
Industry | All | 18 Years and older (Adult, Older Adult) | NCT03126617 | EAP-01-CA204 | April 24, 2017 | June 27, 2018 | |||||||||||
91 | NCT03492268 | Recruiting | Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma |
|
|
Interventional |
Not Applicable |
|
Industry / Other |
|
|
20 | All | 18 Years to 65 Years (Adult, Older Adult) | NCT03492268 | 2018-CART-00CH3(1) | November 20, 2018 | November 20, 2019 | December 1, 2020 | April 10, 2018 | November 27, 2018 |
|
|||
92 | NCT03489525 | Recruiting | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Industry |
|
|
129 | All | 18 Years to 101 Years (Adult, Older Adult) | NCT03489525 | D7900C00001 | MEDI2228 | May 8, 2018 | April 23, 2021 | April 23, 2021 | April 5, 2018 | January 21, 2019 |
|
||
93 | NCT03761108 | Recruiting | First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
56 | All | 18 Years and older (Adult, Older Adult) | NCT03761108 | R5458-ONC-1826 2018-003188-78 |
January 2, 2019 | December 20, 2022 | December 20, 2022 | December 3, 2018 | January 9, 2019 |
|
|||
94 | NCT03665155 | Recruiting | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other |
|
|
30 | All | 21 Years and older (Adult, Older Adult) | NCT03665155 | 18-267 | September 5, 2018 | September 2021 | September 2021 | September 11, 2018 | January 17, 2019 |
|
|||
95 | NCT02654990 | Recruiting | Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Industry |
|
|
240 | All | 18 Years and older (Adult, Older Adult) | NCT02654990 | CLBH589D2222 | PANORAMA_3 | April 27, 2016 | June 10, 2019 | December 15, 2022 | January 13, 2016 | February 15, 2019 |
|
||
96 | NCT02863991 | Recruiting | Oral ONC201 in Relapsed/Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
|
|
42 | All | 18 Years and older (Adult, Older Adult) | NCT02863991 | ONC007 R01FD005402 |
January 1, 2016 | December 31, 2019 | December 31, 2020 | August 11, 2016 | November 14, 2018 |
|
|||
97 | NCT03711864 | Recruiting | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma |
|
|
Interventional |
Phase 1 |
|
Other / Industry |
|
|
15 | All | 18 Years to 80 Years (Adult, Older Adult) | NCT03711864 | YMCART201804 | October 10, 2018 | October 10, 2020 | December 20, 2020 | October 19, 2018 | October 19, 2018 |
|
|||
98 | NCT03773107 | Recruiting | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma |
|
|
Interventional |
Phase 1 Phase 2 |
|
Other / Industry |
|
|
48 | All | 18 Years to 75 Years (Adult, Older Adult) | NCT03773107 | LCI-HEM-MYE-CRD-004 00031040 |
January 3, 2019 | December 31, 2020 | December 31, 2025 | December 12, 2018 | January 10, 2019 |
|
|||
99 | NCT03537222 | Not yet recruiting | Quality of Life in Patients With Multiple Myeloma-validation Study |
|
|
Observational |
|
Other / Industry |
|
|
210 | All | 18 Years and older (Adult, Older Adult) | NCT03537222 | 97107155001701 | June 2018 | December 2019 | December 2019 | May 25, 2018 | June 20, 2018 |
|
||||
100 | NCT02253316 | Recruiting | Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma |
|
|
Interventional |
Phase 2 |
|
Other / Industry |
|
|
240 | All | 18 Years to 70 Years (Adult, Older Adult) | NCT02253316 | 201411060 | January 20, 2015 | November 30, 2019 | August 31, 2024 | October 1, 2014 | January 7, 2019 |
|
† Study has passed its completion date and status has not been verified in more than two years.